Dr. Jorge Cortes joined Bio-Path’s Scientific Advisory Board as its chairman and an inaugural member. A well-established expert in oncology and hematology, Dr. Cortes currently holds several positions at the University of Texas MD Anderson Cancer Center, including Jane and John Justin Distinguished Chair in Leukemia Research, chief of the AML (acute myeloid leukemia) and CML (chronic myelogenous leukemia) sections, and deputy chair of the Leukemia department.
Over the course of his 25-year career specializing in leukemia research, Dr. Cortes has held several prestigious academic appointments at The University of Texas, including associate professor in the Leukemia department at the Graduate School of Biomedical Sciences and chair of the CML section at The University of Texas MD Anderson Cancer Center.
Dr. Cortes has also lent his experience as a consultant to leading pharmaceutical companies such as AstraZeneca on the development of prenyltransferase inhibitors, GlaxoSmithKline on the use of topotecan in MDS (myelodysplastic syndromes) and CMML (chronic myelomonocytic leukemia), and Rhône-Poulenc Rorer (now Sanofi-Aventis) on the use of PEG-asparaginase in adult ALL (acute lymphoblastic leukemia).
Dr. Cortes earned his medical degree from la Facultad de Medicina, Universidad Nacional Autónoma de México and a Bachelor of Science from el Centro Universitario México. He currently serves on the National CML Society’s Medical Advisory Board, as well as on numerous other executive committees and scientific advisory boards for organizations such as the Leukemia & Lymphoma Society and the International CML Foundation.